RP-832c

RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM) . RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF) [1][2].

Product Specifications

CAS Number

[2375823-45-1]

UNSPSC

12352209

Target

Apoptosis; TNF Receptor

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Purity

98.16

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=CC=C3)C(NCC(NCC(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N

Molecular Formula

C68H94N20O11

Molecular Weight

1367.60

References & Citations

[1]Carla Portocarrero, et al; Targeting Immunosuppressive Macrophages in the Cutaneous T-Cell Lymphoma Microenvironment. Blood 2022; 140 (Supplement 1) : 3146–3147.|[2]Ghebremedhin A, et al. A Novel CD206 Targeting Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice. Cells. 2023 Apr 26;12 (9) :1254.